Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH‐EXAMINER as a potential clinical trial endpoint

201951 citationsJournal Articlehybrid Open Access

Authors

The NIH-EXAMINER is sensitive to cognitive changes in presymptomatic familial FTLD and is a promising surrogate endpoint.

Good health and well-being

Published in: Alzheimer s & Dementia

Volume 16, Issue 1, pp. 11-21

Field-Weighted Citation Impact: 4.60